In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
Community PollStarted
Do you offer SERDs as monotherapy or in combination with CDK4/6i for a patient with metastatic HR+, HER2-, ESR1 mutated breast cancer who has progressed on first-line ET + CDK4/6i?
58 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Northwell Health-Lenox Hill Hospital
Answered on
In my practice, when treating patients with advanced hormone receptor-positive (HR+), HER2-negative breast cancer who have progressed on first-line CDK4/6 inhibitors and endocrine therapy, and who harbor ESR1 mutations, I typically consider elacestrant monotherapy as the preferred second-line treatm...
Join for free or sign in to see the full answer